StockData
Soligenix, Inc. logo

Soligenix, Inc. (SNGX) stock

SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$0.22−0.02 (-8.29%)

Close on Nov 20, 2026Market cap $4.79MP/E –Yield –

Soligenix free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Soligenix's free cash flow for the twelve months ending Dec 31, 2025 was -$10.27M. For fiscal 2025 it was -$10.27M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.27M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$2.75M–
Q3 FY2025Sep 30, 2025-$2.93M–
Q3 FY2016Sep 30, 2016-$1.20M–

More Soligenix figures

See a number that looks wrong?